MNKD MannKind Corporation

+0.02  (+2%)
Previous Close 1.1
Open 1.12
Price To Book -1.12
Market Cap 210,316,487
Shares 187,782,578
Volume 1,457,959
Short Ratio
Av. Daily Volume 2,085,380

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved June 27, 2014.
Type 1/2 diabetes
Phase 1 trial completion announced June 7, 2018.
Treprostinil Technosphere
Pulmonary Arterial Hypertension (PAH)

Latest News

  1. MNKD: ADA Presentations: Positive Pediatric Data Lends Support for Anticipated Pivotal Study. Adult Data Highlights Benefits, Safety of Higher Doses
  2. MannKind to Present at the JMP Securities Life Sciences Conference
  3. MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions
  4. Afrezza® (insulin human) Inhalation Powder Approved in Brazil
  5. 2 Healthcare Stocks That Could Double Your Money
  6. The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering
  7. MannKind Announces Afrezza® Distribution Agreement in Australia
  8. Why MannKind Is Up Big Today
  9. MNKD: Product Sales Up 49% on 71% Growth in Demand. Product Margin Continues to Expand
  10. MannKind Corporation (MNKD) Q1 2019 Earnings Call Transcript
  11. Edited Transcript of MNKD earnings conference call or presentation 7-May-19 1:00pm GMT
  12. MannKind: 1Q Earnings Snapshot
  13. MannKind Corporation Reports 2019 First Quarter Financial Results
  14. United Therapeutics (UTHR) Down Despite Q1 Earnings Beat
  15. MannKind Corporation to Hold 2019 First Quarter Financial Results Conference Call on May 7, 2019
  16. MannKind Presents Scientific Data at 28th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE 2019)
  17. MannKind to Present at the H.C. Wainwright Global Life Sciences Conference
  18. MannKind Receives $12.5 Million Milestone Payment from United Therapeutics
  19. Analysts Give Positive Recommendations to MannKind in March
  20. MannKind or Akebia: Who’s Expected to Report Faster EPS Growth?